A Phase I/II Open-Label Study of Molibresib for the Treatment of Relapsed/Refractory Hematologic Malignancies.

Saved in:
Bibliographic Details
Title: A Phase I/II Open-Label Study of Molibresib for the Treatment of Relapsed/Refractory Hematologic Malignancies.
Authors: Dawson MA; Department of Clinical Haematology, Peter MacCallum Cancer Centre, Royal Melbourne Hospital, Melbourne, Victoria, Australia.; The Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria, Australia., Borthakur G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Huntly BJP; University of Cambridge, Cambridge, United Kingdom., Karadimitris A; Hugh and Josseline Langmuir Centre for Myeloma Research, Centre for Haematology, Department of Immunology and Inflammation, Imperial College London and Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, United Kingdom., Alegre A; Hospital Universitario de La Princesa and Quironsalud, Madrid, Spain., Chaidos A; Hugh and Josseline Langmuir Centre for Myeloma Research, Centre for Haematology, Department of Immunology and Inflammation, Imperial College London and Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, United Kingdom., Vogl DT; Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania., Pollyea DA; University of Colorado School of Medicine, Aurora, Colorado., Davies FE; Perlmutter Cancer Center, NYU Langone Medical Center, New York, New York., Morgan GJ; Perlmutter Cancer Center, NYU Langone Medical Center, New York, New York., Glass JL; Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, New York., Kamdar M; University of Colorado School of Medicine, Aurora, Colorado., Mateos MV; Hospital Universitario de Salamanca, IBSAL, CIBERONC, Salamanca, Spain., Tovar N; Hospital Clínic, University of Barcelona, Barcelona, Spain., Yeh P; Department of Clinical Haematology, Peter MacCallum Cancer Centre, Royal Melbourne Hospital, Melbourne, Victoria, Australia.; The Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria, Australia., Delgado RG; Hospital Virgen de la Victoria, Málaga, Spain., Basheer F; Addenbrooke's Hospital, Cambridge, United Kingdom., Marando L; University of Cambridge, Cambridge, United Kingdom., Gallipoli P; Addenbrooke's Hospital, Cambridge, United Kingdom., Wyce A; GSK, Collegeville, Pennsylvania., Krishnatry AS; GSK, Collegeville, Pennsylvania., Barbash O; GSK, Collegeville, Pennsylvania., Bakirtzi E; GSK, Collegeville, Pennsylvania., Ferron-Brady G; GSK, Collegeville, Pennsylvania., Karpinich NO; GSK, Collegeville, Pennsylvania., McCabe MT; GSK, Collegeville, Pennsylvania., Foley SW; GSK, Collegeville, Pennsylvania., Horner T; GSK, Collegeville, Pennsylvania., Dhar A; GSK, Collegeville, Pennsylvania., Kremer BE; GSK, Collegeville, Pennsylvania., Dickinson M; Department of Clinical Haematology, Peter MacCallum Cancer Centre, Royal Melbourne Hospital, Melbourne, Victoria, Australia.; The Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria, Australia.
Source: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2023 Feb 16; Vol. 29 (4), pp. 711-722.
Publication Type: Clinical Trial, Phase II; Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 9502500 Publication Model: Print Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1557-3265
DOI:10.1158/1078-0432.CCR-22-1284